arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Enovis CORP

ENOV
$18.23 ▼ -0.16 (-0.90%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
64 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enovis CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1B
Dividend Yield —
Revenue Growth 3.2% ↘
Op. Margin 3.0% ↗
ROIC -0.1% ↗
FCF / Share $0.54 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield 3.0%
Debt / Equity 0.87
info Valuation on last close. End-of-day price, Sep 23, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$582.78M
↑ +3.2% —
Net Income Profit after all expenses
$-1.19M
↑ +96.8% —
Operating Margin Operating profit as % of sales
3.0%
↑ +169.6% 5th
FCF / Share Free cash flow per share
$0.54
↑ +207.4% —
Long-Term Debt Long-term obligations
$1.28B
↓ -3.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
13
Returns
11
Financial Health →
27
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 64 quarters